Bevacizumab


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intravenous
Metastatic breast cancer
Adult: 10 mg/kg once every 2 wk or 15 mg/kg once every 3 wk via infusion over 90 minutes on the 1st dose and may be infused thereafter over 60 or 30 minutes depending on tolerability, in combination w/ paclitaxel.

Intravenous
Non-small cell lung cancer
Adult: 7.5 mg/kg or 15 mg/kg once every 3 wk via infusion over 90 minutes on the 1st dose and may be infused thereafter over 60 or 30 minutes depending on tolerability. Usually in combination w/ carboplatin and paclitaxel.

Intravenous
Advanced renal cell carcinoma, Metastatic renal cell carcinoma
Adult: 10 mg/kg once every 2 wk via infusion over 90 minutes on the 1st dose and may be infused thereafter over 60 or 30 minutes depending on tolerability, in combination w/ interferon alfa.

Intravenous
Metastatic colorectal cancer
Adult: 5 mg/kg or 10 mg/kg once every 2 wk, or 7.5 mg/kg or 15 mg/kg once every 3 wk via infusion over 90 minutes on the 1st dose and may be infused thereafter over 60 or 30 minutes depending on tolerability. Doses depend on drug combination used in the regimen.

Intravenous
Cervical cancer
Adult: 15 mg/kg every 3 wk via infusion over 90 minutes on the 1st dose and may be infused thereafter over 60 or 30 minutes depending on tolerability, in combination w/ paclitaxel/cisplatin or paclitaxel/topotecan.

Intravenous
Glioblastoma
Adult: 10 mg/kg once every 2 wk via infusion over 90 minutes on the 1st dose and may be infused thereafter over 60 or 30 minutes depending on tolerability.
Hướng dẫn pha thuốc
Dilute in 100 mL of NaCl 0.9%. Final concentration should be 1.4-16.5 mg/mL.
Thận trọng
Patient w/ CV disease, pre-existing HTN, CNS metastases, diabetes, history of arterial thromboembolism; at risk of thrombocytopenia, GI perforation and gall bladder perforation. Discontinue treatment if hypertensive crisis or hypertensive encephalopathy develops. Withhold treatment prior to elective surgery. Do not initiate treatment for at least 28 days after major surgery or until surgical wound is fully healed. Elderly >65 yr. Pregnancy and lactation.
Phản ứng phụ
Gall bladder perforation, ileus, intestinal obstruction, hepatobiliary disorder, GI disorder, arterial thromboembolism, HTN, fatigue or asthenia, pyrexia, pain, mucosal inflammation, abdominal pain, diarrhoea, constipation, nausea, vomiting, anorexia, febrile neutropenia, leucopenia, neutropenia, thrombocytopenia, peripheral sensory neuropathy, dysarthria, headache, dysgeusia, eye disorder, increased lacrimation, venous thromboembolism, dyspnoea, rhinitis, rectal haemorrhage, stomatitis, exfoliative dermatitis, skin discolouration, dry skin, arthralgia, proteinuria, ovarian failure, sepsis, abscess, infection, UTI, anaemia, hypersensitivity infusion reaction, dehydration, CVA, somnolence, syncope, CHF, supraventricular tachycardia, DVT, pulmonary embolism, hypocia, epistaxis, dysphonia, Palmar-plantar erythrodysaesthesia syndrome, fistula, myalgia, muscular weakness, lethargy.
Potentially Fatal: GI perforation, necrotising fasciitis, wound healing and surgical complications, haemorrhage (including haemoptysis, GI bleeding, pulmonary and CNS haemorrhage, vag bleeding, epistaxis).
MonitoringParameters
Monitor BP every 2-3 wk. Monitor for development or worsening of proteinuria/nephritic syndrome w/ urine dipstick.
Tương tác
May increase risk of microangiopathic haemolytic anaemia w/ sunitinib. May increase risk of agranulocytosis and pancytopenia w/ dipyrone. May increase risk of agranulocytosis w/ clozapine. May increase risk of hand-foot skin reaction w/ sorafenib. May increase risk of osteonecrosis of the jaw w/ bisphosphonate derivatives.
Tác dụng
Description: Bevacizumab is a recombinant humanised monoclonal antibody that binds to vascular endothelial growth factor (VEGF). It prevents interaction of VEGF w/ its receptors (Flt-1, KDR) on the surface of endothelial cells & thereby inhibits the angiogenesis that occurs during tumour growth.
Pharmacokinetics:
Distribution: Volume of distribution: 46 mL/kg.
Excretion: Elimination half-life: Approx 20 days.
Bảo quản
Store between 2-8°C. Do not freeze. Protect from light. Reconstituted soln: Store between 2-8°C, stable up to 8 hr.
Phân loại MIMS
Phân loại ATC
L01XC07 - bevacizumab ; Belongs to the class of monoclonal antibodies, other antineoplastic agents. Used in the treatment of cancer.
References
Anon. Bevacizumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/11/2014.

Avastin Injection, Solution (Genentech, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/11/2014.

Avastin Solution for Intravenous Infusion. U.S. FDA. https://www.fda.gov/. Accessed 03/11/2014.

Buckingham R (ed). Bevacizumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/11/2014.

Joint Formulary Committee. Bevacizumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/11/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Bevacizumab. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 03/11/2014.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Bevacizumab từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in